FDA-cleared profile

IRISeg

Intuitive Surgical Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.

Clinical role
Medical-image processing, segmentation, enhancement, measurement, quantification, visualization, or reporting support under professional review.
Images and patients
CT/CTA · Kidneys
Key limitation
Keep in mind: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Kidneys Input: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.
  • Who uses it?Intended users: Qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow.
  • What does the software produce?Output: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.
  • What is its most important limitation?Key limitation: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.

Clinical takeaway. Clinical role: IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
IRISeg receives DICOM-compliant contrast-enhanced CT images, provides manual and machine-learning-enabled image-analysis and segmentation tools, and creates an output file for a three-dimensional model used in preoperative planning and intraoperative display. The kidney CT auto-segmentation tool is indicated for adult patients with contrast-enhanced axial kidney CT images with slice thickness of 3 mm or less.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Medical-image processing, segmentation, enhancement, measurement, quantification, visualization, or reporting support under professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital, clinic, imaging-center, procedural, dental, or other labeled clinical environments.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The performance testing included software verification, machine-learning algorithm performance testing, cybersecurity testing, and design validation testing." … "A total of 81 kidney CT scans were used to evaluate the algorithm.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports software verification and validation, cybersecurity testing, design validation, and bench testing of the kidney CT auto-segmentation algorithm on 81 kidney CT scans, with training/testing independence enforced by scanning institution, against consensus segmentations by three U.S Board Certified Radiologists. 95% two-sided confidence intervals: artery DSC [0.87, 0.90], parenchyma DSC [0.95, 0.97], vein DSC [0.87, 0.89], collecting system MDA [1.3, 1.9]. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The performance testing included software verification, machine-learning algorithm performance testing, cybersecurity testing, and design validation testing." … "A total of 81 kidney CT scans were used to evaluate the algorithm.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not a product-wide endpoint for this system or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K242461 FDA decision evidence for IRISeg

  • DesignFDA 510(k) substantial-equivalence review of the exact submission, device description, indications, and verification or validation documentation.
  • PopulationKidneys
  • Scopeexact submission
  • Tested versionIRISeg Version 3.1
  • IndependenceSponsor or vendor study

K242461

The FDA decision material is manufacturer-submitted regulatory evidence. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K242461 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, surgical, or diagnostic service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported medical images, DICOM metadata, patient and protocol information, and release-specific user inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K242461: IRISeg

  2. Routing

    Source context, not route validation: The exact FDA package describes IRISeg opening and loading DICOM CT imaging files and NIfTI label map files from an accessible storage location, and generating an output file that can be used to render virtual segmented kidney 3D models. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "IRISeg can open and load CT imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and label map files (2D segmented labels) in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location." … "Following the use of IRISeg to segment kidney CT imaging files, the software can be used to generate an output file that can be used to render virtual segmented kidney 3D models.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA 510(k) decision material K242461: IRISeg

  3. AI processing

    Source context, not route validation: The exact FDA package describes IRISeg as a standalone software application whose listed host hardware compatibility is general-purpose computer hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Host Hardware General-purpose computer General-purpose computer Compatibility hardware hardware" … "IRISeg Version 3.1 (“IRISeg”) is a standalone software application created by Intuitive Surgical for segmentation of contrast-enhanced kidney CT images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) decision material K242461: IRISeg

  4. Returned objects

    Source context, not route validation: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K242461: IRISeg

  5. Viewer/worklist/report

    Unresolved route: Images, segmentations, measurements, models, calculations, overlays, or reports that require professional review.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K242461: IRISeg

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes IRISeg as a standalone software application whose listed host hardware compatibility is general-purpose computer hardware. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Host Hardware General-purpose computer General-purpose computer Compatibility hardware hardware" … "IRISeg Version 3.1 (“IRISeg”) is a standalone software application created by Intuitive Surgical for segmentation of contrast-enhanced kidney CT images". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes IRISeg opening and loading DICOM CT imaging files and NIfTI label map files from an accessible storage location, and generating an output file that can be used to render virtual segmented kidney 3D models. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "IRISeg can open and load CT imaging files in DICOM (Digital Imaging and Communications in Medicine) format, and label map files (2D segmented labels) in NIfTI (Neuroimaging Informatics Technology Initiative) format from an accessible storage location." … "Following the use of IRISeg to segment kidney CT imaging files, the software can be used to generate an output file that can be used to render virtual segmented kidney 3D models.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
Intuitive's product security program page describes a coordinated vulnerability disclosure program scoped to its medical devices, supporting software, web services, and mobile applications (reporting to product.security@intusurg.com with PGP), published security advisories with product impact assessments, and a post-market cybersecurity vulnerability monitoring program covering products including da Vinci, Ion, and digital services.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement. Applicant name variants ('Intuitive Surgical Inc.', 'Intuitive Surgical, Inc.') are the identical distinctive name. Exact-release scope is not established.

Training
Only qualified healthcare professionals trained for the exact represented anatomy, modality, and workflow should operate or interpret this product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K242461 before acceptance. Later family features are not evidence for this exact submission.

exact submission · checked 2026-09-04

Interoperability acceptance

The exact FDA material does not establish a complete interoperability contract. Establish and test supported input, output, identity, routing, archive, and downtime behavior locally.

exact submission · checked 2026-09-04

Deployment and security qualification

The exact FDA material does not establish hosting, deployment topology, availability, upgrade path, or service responsibility. Obtain site-specific evidence before procurement.

exact submission · checked 2026-09-04

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs. No exact-product price was found.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor by exact hardware, software, model, algorithm, reconstruction, or configuration version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: The FDA indication states that the output is for visual, non-diagnostic use, requires clinician review, and does not replace final patient-management decisions. Applicability is limited to the exact CT input, adult population, and slice-thickness condition for the automated kidney function.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242461
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Kidneys
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-12-10
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-20Last searched
33Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared or approved configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K242461: IRISeg

    U.S. Food and Drug Administration - Published 2024-12-10 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Intuitive: Product Security / Coordinated Vulnerability Program

    Intuitive Surgical - Accessed 2026-10-27

    Scope: security

Research history

  1. K242461 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260406

Brainomix 360 Hyperdensity

Brainomix Limited

Authorized purpose: Provides volumetric hyperdensity segmentation and quantification as an aid; physicians must review original images.

Modality
CT/CTA
Anatomy
Brain
Decision
2026-06-12
FDA-cleared K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

Mighty Oak Medical

Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.

Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Decision
2026-06-11

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history